Our Pipeline

Our broad pipeline includes multiple targeted therapies that harness the immune system and target specific molecular pathways.

Apollomics, Inc. Pipeline 20240401

IP – Intellectual Property
GBM – Glioblastoma Multiforme
r/r AML – Relapsed or Refractory Acute Myeloid Leukemia
NSCLC – Non-Small Cell Lung Cancer

1 excluding China, Hong Kong and Macau
2 excluding China, Hong Kong and Taiwan
3 excluding China